Clinical Trial Update: Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia [Phase 3]

View source ↗

Summary

Phase 3 study evaluating dose escalation of ACTIMMUNE for Friedreich's Ataxia reported safety, tolerability, and efficacy results; the trial was completed with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Friedreich Ataxia

Drugs mentioned

• ACTIMMUNE (interferon gamma-1b)

Snippet

Sponsor: Amgen | Conditions: Friedreich's Ataxia | Phase 3 | Status: COMPLETED | Results posted: 2017-12-08